View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Apr. 30, 2019	May 24, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Document Period End Date	Apr. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	COOPER COMPANIES INC
Entity Central Index Key	0000711404
Current Fiscal Year End Date	--10-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		49,487,752

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Income Statement [Abstract]
Net sales (Note 2)	$ 654.3	$ 631.3	$ 1,282.4	$ 1,221.3
Cost of sales	221.7	226.8	431.3	445.9
Gross profit	432.6	404.5	851.1	775.4
Selling, general and administrative expense	246.8	247.9	496.8	473.8
Research and development expense	21.0	20.8	42.0	39.7
Amortization of intangibles	36.9	36.7	73.5	72.7
Impairment of intangibles	0.0	24.4	0.0	24.4
Gain on sale of an intangible (Note 5)	(19.0)	0.0	(19.0)	0.0
Operating income	146.9	74.7	257.8	164.8
Interest expense	18.5	18.7	36.6	37.1
Other expense (income), net	0.3	2.0	(0.7)	(1.1)
Income before income taxes	128.1	54.0	221.9	128.8
Provision (benefit) for income taxes (Note 7)	5.7	(6.9)	(3.6)	190.4
Net income (loss)	$ 122.4	$ 60.9	$ 225.5	$ (61.6)
Earnings (loss) per share - basic (in usd per share) (Note 8)	$ 2.48	$ 1.24	$ 4.57	$ (1.26)
Earnings (loss) per share - diluted (in usd per share) (Note 8)	$ 2.45	$ 1.23	$ 4.52	$ (1.26)
Number of shares used to compute earnings (loss) per share:
Basic (shares)	49.4	49.1	49.3	49.0
Diluted (shares)	50.0	49.6	49.9	49.0

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Current assets:
Cash and cash equivalents	$ 104.6	$ 77.7
Trade accounts receivable, net of allowance for doubtful accounts of $17.2 at April 30, 2019 and $19.0 at October 31, 2018	396.2	374.7
Inventories (Note 4)	493.1	468.8
Prepaid expense and other current assets	142.7	169.7
Total current assets	1,136.6	1,090.9
Property, plant and equipment, at cost	2,038.2	1,930.3
Less: accumulated depreciation and amortization	1,005.5	954.3
Property, plant and equipment, net	1,032.7	976.0
Goodwill (Note 5)	2,438.5	2,392.1
Other intangibles, net (Note 5)	1,474.1	1,521.3
Deferred tax assets	60.1	58.4
Other assets	61.4	74.1
Total assets	6,203.4	6,112.8
Current liabilities:
Short-term debt (Note 6)	454.6	37.1
Accounts payable	129.2	146.4
Employee compensation and benefits	83.0	94.0
Other current liabilities	274.1	259.0
Total current liabilities	940.9	536.5
Long-term debt (Note 6)	1,472.3	1,985.7
Deferred tax liabilities	33.3	31.0
Long-term tax payable	124.8	141.5
Accrued pension liability and other	89.9	110.3
Total liabilities	2,661.2	2,805.0
Contingencies (see Note 13)
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0.0	0.0
Common stock, 10 cents par value, shares authorized: 120.0; issued 53.1 at April 30, 2019 and 52.8 at October 31, 2018	5.3	5.3
Additional paid-in capital	1,587.7	1,572.1
Accumulated other comprehensive loss	(416.6)	(430.7)
Retained earnings	2,786.8	2,576.0
Treasury stock at cost: 3.6 shares at April 30, 2019 and 3.6 shares at October 31, 2018	(421.2)	(415.1)
Noncontrolling interests	0.2	0.2
Stockholders’ equity (Note 10)	3,542.2	3,307.8
Total liabilities and stockholders' equity	$ 6,203.4	$ 6,112.8

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 122.4	$ 60.9	$ 225.5	$ (61.6)
Other comprehensive (loss) income:
Foreign currency translation adjustment, net of tax	(18.6)	(43.0)	14.1	59.3
Comprehensive income (loss)	$ 103.8	$ 17.9	$ 239.6	$ (2.3)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 17.2	$ 19.0
Preferred stock, par value (in dollars per share)	$ 0.1	$ 0.1
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	53,100,000	52,800,000
Treasury stock, shares	3,600,000	3,600,000

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests
Beginning Balance (in shares) at Oct. 31, 2017		48.8	3.6
Beginning Balance at Oct. 31, 2017	$ 3,175.8	$ 4.9	$ (415.1)	$ 0.3	$ 1,526.7	$ (375.3)	$ 2,434.2	$ 0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	(122.5)						(122.5)
Other comprehensive income (loss), net of tax	102.3					102.3
Issuance of common stock for stock plans, net (in shares)		0.2
Issuance of common stock for stock plans, net	(10.5)	$ 0.1			(10.6)
Dividends on common stock	(1.4)						(1.4)
Share-based compensation expense	12.7				12.7
Ending Balance (in shares) at Jan. 31, 2018		49.0	3.6
Ending Balance at Jan. 31, 2018	3,156.4	$ 5.0	$ (415.1)	0.3	1,528.8	(273.0)	2,310.3	0.1
Beginning Balance (in shares) at Oct. 31, 2017		48.8	3.6
Beginning Balance at Oct. 31, 2017	3,175.8	$ 4.9	$ (415.1)	0.3	1,526.7	(375.3)	2,434.2	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	(61.6)
Ending Balance (in shares) at Apr. 30, 2018		49.1	3.6
Ending Balance at Apr. 30, 2018	3,188.0	$ 5.0	$ (415.1)	0.3	1,542.5	(316.0)	2,371.2	0.1
Beginning Balance (in shares) at Jan. 31, 2018		49.0	3.6
Beginning Balance at Jan. 31, 2018	3,156.4	$ 5.0	$ (415.1)	0.3	1,528.8	(273.0)	2,310.3	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	60.9						60.9
Other comprehensive income (loss), net of tax	(43.0)					(43.0)
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	0.1				0.1
Share-based compensation expense	13.6				13.6
Ending Balance (in shares) at Apr. 30, 2018		49.1	3.6
Ending Balance at Apr. 30, 2018	3,188.0	$ 5.0	$ (415.1)	0.3	1,542.5	(316.0)	2,371.2	0.1
Beginning Balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning Balance at Oct. 31, 2018	3,307.8	$ 5.0	$ (415.1)	0.3	1,572.1	(430.7)	2,576.0	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	103.2						103.2
Other comprehensive income (loss), net of tax	32.7					32.7
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	(9.0)				(9.0)
Dividends on common stock	(1.5)						(1.5)
Share-based compensation expense	11.7				11.7
Treasury stock repurchase	(6.1)		$ (6.1)
Ending Balance (in shares) at Jan. 31, 2019		49.3	3.6
Ending Balance at Jan. 31, 2019	3,425.5	$ 5.0	$ (421.2)	0.3	1,574.8	(398.0)	2,664.4	0.2
Beginning Balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning Balance at Oct. 31, 2018	3,307.8	$ 5.0	$ (415.1)	0.3	1,572.1	(430.7)	2,576.0	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	225.5
Ending Balance (in shares) at Apr. 30, 2019		49.5	3.6
Ending Balance at Apr. 30, 2019	3,542.2	$ 5.0	$ (421.2)	0.3	1,587.7	(416.6)	2,786.8	0.2
Beginning Balance (in shares) at Jan. 31, 2019		49.3	3.6
Beginning Balance at Jan. 31, 2019	3,425.5	$ 5.0	$ (421.2)	0.3	1,574.8	(398.0)	2,664.4	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Cooper stockholders	122.4						122.4
Other comprehensive income (loss), net of tax	(18.6)					(18.6)
Issuance of common stock for stock plans, net (in shares)		0.2
Issuance of common stock for stock plans, net	4.5				4.5
Share-based compensation expense	8.4				8.4
Ending Balance (in shares) at Apr. 30, 2019		49.5	3.6
Ending Balance at Apr. 30, 2019	$ 3,542.2	$ 5.0	$ (421.2)	$ 0.3	$ 1,587.7	$ (416.6)	$ 2,786.8	$ 0.2

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Cash flows from operating activities:
Net income (loss)	$ 225.5	$ (61.6)
Depreciation and amortization	139.5	135.6
Gain on sale of an intangible (Note 5)	(19.0)	0.0
Impairment of intangibles	0.0	24.4
Increase in operating capital	(19.7)	(187.6)
Other non-cash items	(9.7)	286.3
Net cash provided by operating activities	316.6	197.1
Cash flows from investing activities:
Purchases of property, plant and equipment	(131.9)	(97.9)
Acquisitions of businesses and assets, net of cash acquired, and other	(50.8)	(1,320.7)
Net cash used in investing activities	(182.7)	(1,418.6)
Cash flows from financing activities:
Proceeds from long-term debt	424.8	1,946.1
Repayments of long-term debt	(938.8)	(650.1)
Net proceeds from short-term debt	417.4	16.4
Net payments related to share-based compensation awards	(4.3)	(10.5)
Dividends on common stock	(1.5)	(1.5)
Repurchase of common stock	(6.1)	0.0
Debt acquisition costs	(0.2)	(3.9)
Payment of contingent consideration	0.0	(0.2)
Net cash (used in) provided by financing activities	(108.7)	1,296.3
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(0.5)	1.3
Net increase in cash, cash equivalents and restricted cash	24.7	76.1
Cash, cash equivalents and restricted cash at beginning of period	80.2	88.8
Cash, cash equivalents and restricted cash at end of period	104.9	164.9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Total cash, cash equivalents, and restricted cash	$ 80.2	$ 88.8

General	6 Months Ended
General	Apr. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited interim consolidated condensed financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2018. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance. The terms "the Company", "we", "us", and "our" are used to refer collectively to the Cooper Companies, Inc. and its subsidiaries. Accounting Pronouncements Recently Adopted In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is now presented in the same income statement line as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below operating income. The Company adopted this guidance on November 1, 2018, and it did not have a material impact on the Company’s reported financial results. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which requires entities to recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The ASU changes the timing of the recognition of the income tax consequences of non-inventory transfers which under current guidance defers the income tax consequences until the asset is sold to an outside party or otherwise recognized. The guidance for the amendments of ASU 2016-16 requires companies to apply a modified retrospective approach with a cumulative catch-up adjustment to opening retained earnings in the period of adoption. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis. The Company recorded the cumulative effect of the change as a decrease to retained earnings of approximately $13.3 million. The cumulative effect adjustment represents the recognition of unrecognized income tax effects from intra-entity transfers of assets other than inventory that occurred prior to the date of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU requires revenue recognition to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or alternatively, the modified retrospective transition method whereby the company recognizes the cumulative effect of initially applying the guidance as an opening balance sheet adjustment to equity in the period of initial application. This alternative approach must be supplemented by additional disclosures. We adopted ASU 2014-09 on November 1, 2018, using the modified retrospective transition method. We did not recognize any cumulative effect of initially applying the new revenue standard as an adjustment to our opening balance of retained earnings due to its immaterial impact. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. There was no material impact of ASC 606 to our financial statements during the three and six months ended April 30, 2019. We do not expect the adoption of the new revenue standard to have a material impact to our net income on an ongoing basis. The Company applies the provisions of Accounting Standards Codification (ASC) 606-10 or ASU 2014-09, Revenue from Contracts with Customers, and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled. In order to achieve that core principle, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 2. Revenue Recognition. Accounting Pronouncements Issued Not Yet Adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended ASC 808 and ASC 606 to clarify that transactions in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We are currently evaluating the impact of ASU 2018-18 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other - Internal Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This guidance requires companies to apply the internal-use software guidance in ASC 350-40 to implementation costs incurred in a hosting arrangement that is a service contract to determine whether to capitalize certain implementation costs or expense them as incurred. We are currently evaluating the impact of ASU 2018-15 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements, which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements, which further clarifies the determination of fair value of leases and modifies transition disclosure requirements for changes in accounting principles and other technical updates. This standard is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. We anticipate this standard to have a material impact on our Consolidated Balance Sheets and related disclosures due to the recognition of ROU assets and lease liabilities for operating leases. However, we do not expect adoption to have a material impact on our Consolidated Income Statements. We are continuing to assess and evaluate the potential impacts of the standard as well as the election of transition method and certain practical expedients available within the ASU. We are in the process of documenting and analyzing our lease contracts, assessing business processes and controls, implementing a system solution and completing our analysis of information necessary to determine the impact to the consolidated financial statements. Accounts Receivable Factoring Program We may factor certain designated trade receivables with one or more third party financial institutions pursuant to a factoring agreement. These are non-recourse factoring arrangements to assist us in managing operating cash flow and meet the requirements to be accounted for as sales in accordance with the “Transfers and Servicing” guidance in ASC 860, where the Company’s continuing involvement subsequent to the transfer is limited to providing certain servicing and collection actions on behalf of the purchasers of the designated trade receivables. Proceeds from amounts factored by the Company are recorded as an increase to cash and a reduction to accounts receivable outstanding in the Company's Consolidated Balance Sheets. Cash flows attributable to factoring are reflected as cash flows from operating activities in the Company’s Consolidated Statements of Cash Flows. Factoring fees associated with the sale of factored receivables for the three and six months ended April 30, 2019 were $0.5 million and $0.9 million respectively and were minimal for the three and six months ended April 30, 2018.

Revenue Recognition	6 Months Ended
Revenue Recognition	Apr. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Product Revenue, Net The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note14. Business Segment Information, for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liability. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in the consolidated statements of income of the Company. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $10.6 million at April 30, 2019 which is included in Accrued liabilities on our Condensed Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract balances The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.

Acquisitions

6 Months Ended

Apr. 30, 2019

Business Combinations [Abstract]

Acquisitions

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2019 and 2018:



(In millions)	April 30, 2019		October 31, 2018
Technology	$	10.0	$	—
Customer relationships	7.5		23.5
Trademarks	9.7		100.0
Composite intangible asset	—		1,061.9
Other	—		4.2
Total identifiable intangible assets	$	27.2	$	1,189.6
Goodwill	35.8		70.6
Net tangible assets	1.3		59.6
Total purchase price	$	64.3	$	1,319.8

All the acquisitions were funded by cash generated from operations or facility borrowings.

For business acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For assets acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition.

We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new or complementary products and services.

Fiscal Year 2019

On December 31, 2018, CooperSurgical completed the acquisition of Incisive Surgical Inc., a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure. The purchase price allocation is preliminary and we are in the process of finalizing information primarily related to taxes and the corresponding impact on goodwill.

On December 28, 2018, CooperVision completed the acquisition of Blanchard Contact Lenses. Blanchard is a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio. The purchase price allocation is preliminary and we are in the process of finalizing information primarily related to accrued liabilities, other assets, taxes and the corresponding impact on goodwill.

The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our consolidated results of operations.

Fiscal Year 2018

PARAGARD

On November 1, 2017, CooperSurgical acquired the assets of the PARAGARD Intrauterine Device (IUD) business (PARAGARD) from Teva Pharmaceuticals Industries Limited for $1.1 billion. This asset acquisition broadened and strengthened CooperSurgical's product portfolio. PARAGARD^® is the only hormone-free, long lasting, reversible contraceptive approved by the United States Food and Drug Administration (FDA) available in the United States.

The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model:



(In millions)	Relative Fair Value
Composite intangible asset ⁽¹⁾	$	1,061.9
Assembled workforce intangible asset⁽²⁾	1.2
Property, plant and equipment	2.0
Inventory ⁽³⁾	47.3
Other assets	9.4
Total assets acquired	$	1,121.8
Less: liabilities assumed	16.4
Total Purchase Price	$	1,105.4

The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees.

⁽¹⁾Composite Intangible asset consists of technology, trade name, New Drug Application (NDA) approval and physician relationships, which have been valued as a single composite intangible asset as they are inextricably linked. The composite asset was identified as the primary asset acquired, was valued using the Multi-Period Excess Earnings Method and will be amortized over 15 years.

⁽²⁾An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years.

⁽³⁾Inventory relative fair value includes step up of $45.4 million.

Other Acquisitions

On April 3, 2018, CooperSurgical completed the acquisition of The LifeGlobal Group (LifeGlobal). LifeGlobal was a privately held company that specializes primarily in in-vitro fertilization (IVF) media. LifeGlobal’s product categories include media products as well as IVF laboratory air filtration products and dishware. We have completed the purchase price allocation for this acquisition.

On January 4, 2018, CooperVision acquired Blueyes Ltd, a long-standing distribution partner, with a leading position in the distribution of contact lenses to the Optical and Pharmacy sector in Israel. We have completed the purchase price allocation for this acquisition.

On December 1, 2017, CooperVision acquired Paragon Vision Sciences, a leading provider of orthokeratology (ortho-k) specialty contact lenses and oxygen permeable rigid contact lens materials. Ortho-k contact lenses are overnight lenses which enable corneal topography correction for myopia (nearsightedness) patients. We have completed the purchase price allocation for this acquisition.

Inventories

6 Months Ended

Apr. 30, 2019

Inventory Disclosure [Abstract]

Inventories



(In millions)	April 30, 2019		October 31, 2018
Raw materials	$	122.6	$	112.5
Work-in-process	12.3		12.6
Finished goods	358.2		343.7
	$	493.1	$	468.8

Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

6 Months Ended

Apr. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Goodwill



(In millions)	CooperVision			CooperSurgical			Total
Balance at October 31, 2017	$	1,735.7		$	619.1		$	2,354.8
Net additions during the year ended October 31, 2018	36.8			34.4			71.2
Translation	(29.6		)	(4.3		)	(33.9		)
Balance at October 31, 2018	1,742.9			649.2			2,392.1
Net additions during the six months ended April 30, 2019	13.8			22.0			35.8
Translation	11.2			(0.6		)	10.6
Balance at April 30, 2019	$	1,767.9		$	670.6		$	2,438.5

During the three months ended April 30, 2019, there was a change in the reporting units as a result of realignment in the internal reporting structure of the business around markets and customers at CooperSurgical. As such, Cooper Surgical has evolved into two reporting units, namely, Office/Surgical and Fertility, which reflects management oversight of operations. These reporting units, including CooperVision, will be tested for potential goodwill impairment annually as of the third quarter of each fiscal year. The change in reporting units did not result in a change in operating segments. We allocated CooperSurgical's goodwill based on relative fair values utilizing the discounted cash flow method and guideline public company method as our allocation base, and the allocated fair values exceeded the carrying values for each of the three reporting units as of April 30, 2019.

The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs, or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill and evaluates its goodwill balances and tests them for impairment in accordance with related accounting standards. The Company performs impairment tests of goodwill at the reporting unit level, which is one level below operating segments. Reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management. Under the impairment test, if a reporting unit’s carrying amount exceeds its estimated fair value, goodwill impairment is recognized to the extent that the carrying amount of goodwill exceeds the fair value of the goodwill. The Company performed its annual impairment assessment in its third quarters of fiscal 2018 and fiscal 2017 respectively, and its analysis indicated that the Company had no impairment of goodwill.

Other Intangible Assets



	April 30, 2019				October 31, 2018
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (In years)

Intangible assets with definite lives:
Trademarks	$	147.8	$	22.0	$	138.1	$	16.9	14
Composite intangible asset	1,061.9		106.1		1,061.9		70.8		15
Technology	397.9		206.1		387.2		190.7		11
Customer relationships	357.7		181.3		350.0		168.6		13
License and distribution rights and other⁽¹⁾	67.3		51.9		74.9		52.7		7
	2,032.6		$	567.4	2,012.1		$	499.7	14
Less: accumulated amortization and translation	567.4				499.7
Intangible assets with definite lives, net	1,465.2				1,512.4

Intangible assets with indefinite lives, net ⁽²⁾	8.9				8.9

Total other intangible assets, net	$	1,474.1			$	1,521.3

⁽¹⁾In the second quarter of fiscal 2019, CooperSurgical sold an exclusive distribution right to distribute Filshie Clip System in the U.S. for $21.0 million and recognized a gain of $19.0 million.

⁽²⁾Intangible assets with indefinite lives include trademark and technology intangible assets.

Balances include foreign currency translation adjustments.

As of April 30, 2019, the estimation of amortization expenses for intangible assets with definite lives is as follows:



Fiscal years:	(In millions)
Remainder of 2019	$	71.8
2020	135.5
2021	134.2
2022	132.4
2023	130.1
Thereafter	861.2
Total remaining amortization for intangible assets with definite lives	$	1,465.2

Debt

6 Months Ended

Apr. 30, 2019

Debt Disclosure [Abstract]

Debt



(In millions)	April 30, 2019			October 31, 2018
Overdraft and other credit facilities	$	54.7		$	37.1
Term loans	400.0			—
Less: unamortized debt issuance cost	(0.1		)	—
Short-term Debt	$	454.6		$	37.1

Revolving credit	$	—		$	439.0
Term loans	1,475.0			1,550.0
Other	0.2			0.2
Less: unamortized debt issuance cost	(2.9		)	(3.5		)
Long-term Debt	$	1,472.3		$	1,985.7

Total Debt	$	1,926.9		$	2,022.8

$400 million Term Loan on November 1, 2018

On November 1, 2018, the Company entered into a 364-day, $400.0 million, senior unsecured term loan agreement by and among the Company, the lenders party thereto and PNC Bank, National Association, as administrative agent which matures on October 31, 2019 (the 2018 Term Loan Agreement). The Company used the funds to partially repay outstanding borrowings under the 2016 Revolving Credit Facility. At April 30, 2019, we had $400.0 million outstanding under the 2018 Term Loan Agreement.

Amounts outstanding under the 2018 Term Loan Agreement will bear interest, at the Company's option, at either the base rate, or the adjusted LIBO rate (each as defined in the 2018 Term Loan Agreement), plus, in each case, an applicable rate of 0.00% in respect of base rate loans and 0.60% in respect of adjusted LIBO rate loans. The weighted average interest rate for the three months and six months ended April 30, 2019 were 3.10% and 3.04%, respectively.

The 2018 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2018 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below.

$1.425 billion Term Loan on November 1, 2017

On November 1, 2017, in connection with the PARAGARD acquisition, we entered into a five-year, $1.425 billion, senior unsecured term loan agreement (the 2017 Term Loan Agreement) by and among the Company, the lenders party thereto and DNB Bank ASA, New York Branch, as administrative agent which matures on November 1, 2022. The Company used part of the facility to fund the PARAGARD acquisition and used the remainder of the funds to partially repay outstanding borrowings under our revolving credit agreement.

Amounts outstanding under the 2017 Term Loan Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the 2017 Term Loan Agreement), plus, in each case, an applicable rate of, between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio as defined in the 2017 Term Loan Agreement.

The 2017 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2017 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below. At April 30, 2019, we had $1.425 billion outstanding under the 2017 Term Loan Agreement.

Revolving Credit and Term Loan Agreement on March 1, 2016

On March 1, 2016, we entered into a Revolving Credit and Term Loan Agreement (the 2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion (the 2016 Revolving Credit Facility) and a term loan facility in an aggregate principal amount of $830.0 million (the 2016 Term Loan Facility), each of which, unless terminated earlier, mature on March 1, 2021. In addition, we have the ability from time to time to request an increase to the size of the 2016 Revolving Credit Facility or establish one or more new term loans under the 2016 Term Loan Facility in an aggregate amount up to $750.0 million, subject to the discretionary participation of the lenders.

Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement.

We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the 2016 Revolving Credit Facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement.

At April 30, 2019, we had $50.0 million outstanding under the 2016 Term Loan Facility and $999.5 million available under the 2016 Revolving Credit Facility.

The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2016 Credit Agreement):


•	Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.


•	Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00.

At April 30, 2019, we were in compliance with the Interest Coverage Ratio at 11.17 to 1.00 and the Total Leverage Ratio at 1.99 to 1.00 for 2018 Term Loan Agreement, the 2017 Term Loan Agreement, and the 2016 Credit Agreement. The interest rate on the 2017 and 2016 term loans was 3.75% at April 30, 2019.

Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 for more details.

Income Taxes	6 Months Ended
Income Taxes	Apr. 30, 2019
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Taxes	Income Taxes Recent Tax Legislation The 2017 Act was enacted into law on December 22, 2017 and significantly changes existing U.S. tax law. The 2017 Act adopts a territorial tax system, imposes a mandatory one-time transition tax on earnings of foreign subsidiaries that were previously indefinitely reinvested, and reduces the U.S. federal statutory tax rate from 35% to 21%. For second quarter of fiscal 2019, the Company has utilized the enacted U.S. federal statutory tax rate of 21%. The 2017 Act includes several provisions that are effective for our fiscal 2019: (i) tax on global intangible low-taxed income (GILTI) of foreign subsidiaries, (ii) tax on certain payments between a U.S. corporation and its foreign subsidiaries referred to as the base erosion and anti-abuse tax (BEAT), (iii) limitation on the tax deduction for interest payments, and (iv) expanded limitation on the tax deduction for compensation paid to certain executives. The 2017 Act was effective in the first quarter of fiscal 2018. During the first quarter of fiscal 2019, we recorded tax benefit of $4.4 million in our financial statements to finalize the tax effects of the 2017 Act pursuant to SAB 118. The Company is no longer asserting that earnings from our foreign subsidiaries are indefinitely reinvested. The 2017 Act imposes a new tax on foreign earnings and profits in excess of a deemed return on tangible assets of foreign subsidiaries referred to as GILTI which is effective in fiscal 2019. In accordance with FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, the Company made an accounting policy election to recognize the tax expense related to GILTI in the year the tax is incurred. Effective Tax Rate The Company's effective tax rates were an expense of 4.5% and a benefit of 12.9% for the second quarters of fiscal 2019 and fiscal 2018, respectively, and a benefit of 1.7% and an expense of 147.8% for the first six months of fiscal 2019 and 2018, respectively. The increase in our effective tax rate for the second quarter of fiscal 2019 compared to fiscal 2018 was primarily due to the inclusion of earnings from our foreign subsidiaries pursuant to the GILTI provisions that became effective in fiscal 2019. The decrease in our effective tax rate for the first six months of fiscal 2019 compared to fiscal 2018 was primarily due to the provisional charge of $202.0 million relating to the 2017 Act that was recorded in the first quarter of fiscal 2018. Our effective tax rate for the first six months of fiscal 2019 was lower than the U.S. statutory rate because of discrete tax benefits and a favorable mix of income from our foreign jurisdictions with lower tax rates. Total discrete tax benefits for the first six months of fiscal 2019 were $23.1 million primarily relating to settlement of tax audits, revisions to the provisional tax charges relating to the 2017 Act, and excess tax benefits from share-based compensation. Our effective tax rate for the first six months of fiscal 2018 was higher than the U.S. statutory rate because of the discrete tax expense relating to the 2017 Act, which was partially offset by a favorable mix of income from our foreign jurisdictions with lower tax rates and an excess tax benefit from share-based compensation. We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. As of April 30, 2019, and October 31, 2018, Cooper had unrecognized tax benefits of $49.1 million and $68.9 million, respectively. The decrease is primarily related to settling prior year tax audits, partially offset by additions to current period transfer pricing reserves. It is our policy to recognize interest and penalties directly related to income taxes as additional income tax expense. It is reasonably possible that $3.1 million of unrecognized tax benefits could be settled during the next twelve months. The Company is subject to U.S. Federal income tax examinations for fiscal 2015 through 2018 and the Internal Revenue Service is currently auditing our U.S. Consolidated Corporation Income Tax Returns for fiscal 2015 and 2016. The Company remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2015 through 2018.

Earnings Per Share

6 Months Ended

Apr. 30, 2019

Earnings Per Share [Abstract]

Earnings Per Share

Earnings (Loss) Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2019		2018		2019		2018
Net income (loss)	$	122.4	$	60.9	$	225.5	$	(61.6	)
Basic:
Weighted average common shares	49.4		49.1		49.3		49.0
Basic earnings (loss) per share	$	2.48	$	1.24	$	4.57	$	(1.26	)
Diluted:
Weighted average common shares	49.4		49.1		49.3		49.0
Effect of potential dilutive shares	0.6		0.5		0.6		—
Diluted weighted average common shares*	50.0		49.6		49.9		49.0
Diluted earnings (loss) per share attributable to Cooper stockholders	$	2.45	$	1.23	$	4.52	$	(1.26	)
*The number of diluted weighted average common shares used to calculate fiscal 2018 six months diluted loss per share excludes all potentially dilutive instrument because they would be antidilutive due to the net loss position.

The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:



Periods Ended April 30,	Three Months				Six Months
(In thousands, except exercise prices)	2019		2018		2019	2018
Number of stock option shares excluded	198		199		322	1,145
Range of exercise prices	$	254.77	$	229.66	$226.30-$254.77	$15.83-$229.66
Numbers of restricted stock units excluded	25		81		26	575

Share-Based Compensation Plans

6 Months Ended

Apr. 30, 2019

Share-based Compensation [Abstract]

Share-Based Compensation Plans

Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2018. The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2019		2018		2019		2018
Selling, general and administrative expense	$	6.1	$	12.8	$	15.3	$	23.6
Cost of sales	1.4		0.3		2.9		1.6
Research and development expense	0.9		0.5		1.9		1.1
Total share-based compensation expense	$	8.4	$	13.6	$	20.1	$	26.3
Related income tax benefit	$	1.1	$	3.1	$	2.9	$	5.6

Employee Stock Purchase Plan

On March 18, 2019, the Company received stockholder approval of the Employee Stock Purchase Plan (“ESPP”). The first offering period is for U.S. employees and is expected to begin on November 4, 2019. The purpose of the ESPP is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at 85% of the market price on the last business day of each offering period by means of accumulated payroll deductions. Payroll deductions will be limited to maximum of 15% of the employee’s eligible compensation, not to exceed $21,250 in any one calendar year. The ESPP would initially authorize the issuance of 1,000,000 shares of common stock. These shares will be made available from shares of common stock reacquired by the Company as Treasury Stock. At April 30, 2019, there were approximately 3.6 million Treasury shares.

Stockholders' Equity

6 Months Ended

Apr. 30, 2019

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive (Loss) Income:



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2017	$	(353.7	)	$	(21.6	)	$	(375.3	)
Gross change in value during the year ended October 31, 2018	(58.5		)	11.0			(47.5		)
Tax effect for the period	—			(3.1		)	(3.1		)
ASU 2018-02 adoption⁽¹⁾	—			(4.8		)	(4.8		)
Balance at October 31, 2018	$	(412.2	)	$	(18.5	)	$	(430.7	)
Gross change in value during the six months ended April 30, 2019	14.1			—			14.1
Balance at April 30, 2019	$	(398.1	)	$	(18.5	)	$	(416.6	)


⁽¹⁾	Represents reclassification to retained earnings from adoption of ASU 2018-02. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 for more details.

Share Repurchases

In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements.

We did not repurchase shares in the second quarter of fiscal 2019. During the first quarter of fiscal 2019, we repurchased 24.5 thousand shares of the Company's common stock for $6.1 million, at an average purchase price of $248.70 per share. We did not repurchase shares during the fiscal year ended October 31, 2018. At April 30, 2019, $557.4 million remains authorized for repurchase under the program.

Dividends

We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 8, 2019, to stockholders of record on January 22, 2019.

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Apr. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. At April 30, 2019 and October 31, 2018, the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of our revolving credit facility and term loans approximates fair value estimated based on current market rates (Level 2). The Company did not have any derivative assets or liabilities that may include interest rate swaps, cross currency swaps or foreign currency forward contracts as of April 30, 2019 and October 31, 2018. Nonrecurring fair value measurements The Company uses fair value measures when determining assets and liabilities acquired in an acquisition as described in Note 3. Acquisitions which are considered a Level 3 measurement. The Company also used fair value measures to allocate goodwill upon the split of our reporting units as discussed in Note 5. Intangible Assets which was considered a Level 3 measurement.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefits

6 Months Ended

Apr. 30, 2019

Retirement Benefits, Description [Abstract]

Employee Benefits

Cooper’s Retirement Income Plan (the Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

Our results of operations for the three and six months ended April 30, 2019 and 2018, reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2019			2018			2019			2018
Service cost	$	2.7		$	2.7		$	5.4		$	5.4
Interest cost	1.3			1.3			2.5			2.5
Expected return on plan assets	(2.3		)	(2.3		)	(4.6		)	(4.6		)
Recognized net actuarial loss	0.4			0.4			0.8			0.8
Net periodic pension cost	$	2.1		$	2.1		$	4.1		$	4.1

We contributed $2.5 million to the Plan in the first half of fiscal 2019 and expect to contribute $7.5 million during the remainder of fiscal 2019. We contributed $2.5 million to the Plan in the first half of fiscal 2018. The expected rate of return on Plan assets for determining net periodic pension cost is 8%.

Contingencies	6 Months Ended
Contingencies	Apr. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision. In July 2018, the Court approved the plaintiffs’ motion for preliminary approval of the settlement, and the Company paid the $3.0 million settlement amount into an escrow account. The settlement remains subject to final Court approval at a future hearing to be set by the Court. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Business Segment Information

6 Months Ended

Apr. 30, 2019

Segment Reporting [Abstract]

Business Segment Information

Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.

Total identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2019			2018			2019			2018
CooperVision net sales by category:
Toric lens	$	155.3		$	150.8		301.3			288.6
Multifocal lens	49.7			49.1			98.7			96.1
Single-use sphere lens	135.3			124.4			267.3			240.7
Non single-use sphere and other	143.9			143.2			287.0			286.9
Total CooperVision net sales	484.2			467.5			954.3			912.3
CooperSurgical net sales by category:
Office and surgical procedures	105.7			97.9			201.4			186.0
Fertility	64.4			65.9			126.7			123.0
CooperSurgical net sales	170.1			163.8			328.1			309.0
Total net sales	$	654.3		$	631.3		$	1,282.4		$	1,221.3
Operating income:
CooperVision	$	125.5		$	123.5		$	241.7		$	235.8
CooperSurgical	31.1			(29.8		)	38.3			(39.2		)
Corporate	(9.7		)	(19.0		)	(22.2		)	(31.8		)
Total operating income	146.9			74.7			257.8			164.8
Interest expense	18.5			18.7			36.6			37.1
Other expense (income), net	0.3			2.0			(0.7		)	(1.1		)
Income before income taxes	$	128.1		$	54.0		$	221.9		$	128.8



(In millions)	April 30, 2019		October 31, 2018
Total identifiable assets:
CooperVision	$	3,833.3	$	3,746.0
CooperSurgical	2,191.4		2,201.7
Corporate	178.7		165.1
Total	$	6,203.4	$	6,112.8

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2019		2018		2019		2018
Net sales to unaffiliated customers by country of domicile:
United States	$	305.9	$	293.2	$	584.9	$	554.6
Europe	209.5		210.4		419.2		413.8
Rest of world	138.9		127.7		278.3		252.9
Total	$	654.3	$	631.3	$	1,282.4	$	1,221.3



(In millions)	April 30, 2019		October 31, 2018
Net property, plant and equipment by country of domicile:
United States	$	558.7	$	516.7
Europe	345.6		340.7
Rest of world	128.4		118.6
Total	$	1,032.7	$	976.0

General (Policies)	6 Months Ended
General (Policies)	Apr. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Pronouncements Issued Not Yet Adopted and Accounting Pronouncements Recently Adopted	Accounts Receivable Factoring Program We may factor certain designated trade receivables with one or more third party financial institutions pursuant to a factoring agreement. These are non-recourse factoring arrangements to assist us in managing operating cash flow and meet the requirements to be accounted for as sales in accordance with the “Transfers and Servicing” guidance in ASC 860, where the Company’s continuing involvement subsequent to the transfer is limited to providing certain servicing and collection actions on behalf of the purchasers of the designated trade receivables. Proceeds from amounts factored by the Company are recorded as an increase to cash and a reduction to accounts receivable outstanding in the Company's Consolidated Balance Sheets. Cash flows attributable to factoring are reflected as cash flows from operating activities in the Company’s Consolidated Statements of Cash Flows. Factoring fees associated with the sale of factored receivables for the three and six months ended April 30, 2019 were $0.5 million and $0.9 million respectively and were minimal for the three and six months ended April 30, 2018.
Revenue Recognition	Product Revenue, Net The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note14. Business Segment Information, for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liability. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in the consolidated statements of income of the Company. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $10.6 million at April 30, 2019 which is included in Accrued liabilities on our Condensed Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract balances The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.

Acquisitions Acquisitions (Tables)

6 Months Ended

Apr. 30, 2019

Business Combinations [Abstract]

Schedule of Acquisitions

The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model:



(In millions)	Relative Fair Value
Composite intangible asset ⁽¹⁾	$	1,061.9
Assembled workforce intangible asset⁽²⁾	1.2
Property, plant and equipment	2.0
Inventory ⁽³⁾	47.3
Other assets	9.4
Total assets acquired	$	1,121.8
Less: liabilities assumed	16.4
Total Purchase Price	$	1,105.4

The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees.

⁽²⁾An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years.

⁽³⁾Inventory relative fair value includes step up of $45.4 million.

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2019 and 2018:



(In millions)	April 30, 2019		October 31, 2018
Technology	$	10.0	$	—
Customer relationships	7.5		23.5
Trademarks	9.7		100.0
Composite intangible asset	—		1,061.9
Other	—		4.2
Total identifiable intangible assets	$	27.2	$	1,189.6
Goodwill	35.8		70.6
Net tangible assets	1.3		59.6
Total purchase price	$	64.3	$	1,319.8

Inventories (Tables)

6 Months Ended

Apr. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories



(In millions)	April 30, 2019		October 31, 2018
Raw materials	$	122.6	$	112.5
Work-in-process	12.3		12.6
Finished goods	358.2		343.7
	$	493.1	$	468.8

Intangible Assets (Tables)

6 Months Ended

Apr. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill



(In millions)	CooperVision			CooperSurgical			Total
Balance at October 31, 2017	$	1,735.7		$	619.1		$	2,354.8
Net additions during the year ended October 31, 2018	36.8			34.4			71.2
Translation	(29.6		)	(4.3		)	(33.9		)
Balance at October 31, 2018	1,742.9			649.2			2,392.1
Net additions during the six months ended April 30, 2019	13.8			22.0			35.8
Translation	11.2			(0.6		)	10.6
Balance at April 30, 2019	$	1,767.9		$	670.6		$	2,438.5

Schedule of Other Intangible Assets

Other Intangible Assets



	April 30, 2019				October 31, 2018
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (In years)

Intangible assets with definite lives:
Trademarks	$	147.8	$	22.0	$	138.1	$	16.9	14
Composite intangible asset	1,061.9		106.1		1,061.9		70.8		15
Technology	397.9		206.1		387.2		190.7		11
Customer relationships	357.7		181.3		350.0		168.6		13
License and distribution rights and other⁽¹⁾	67.3		51.9		74.9		52.7		7
	2,032.6		$	567.4	2,012.1		$	499.7	14
Less: accumulated amortization and translation	567.4				499.7
Intangible assets with definite lives, net	1,465.2				1,512.4

Intangible assets with indefinite lives, net ⁽²⁾	8.9				8.9

Total other intangible assets, net	$	1,474.1			$	1,521.3

Finite-lived Intangible Assets Amortization Expense

As of April 30, 2019, the estimation of amortization expenses for intangible assets with definite lives is as follows:



Fiscal years:	(In millions)
Remainder of 2019	$	71.8
2020	135.5
2021	134.2
2022	132.4
2023	130.1
Thereafter	861.2
Total remaining amortization for intangible assets with definite lives	$	1,465.2

Debt (Tables)

6 Months Ended

Apr. 30, 2019

Debt Disclosure [Abstract]

Schedule of Debt



(In millions)	April 30, 2019			October 31, 2018
Overdraft and other credit facilities	$	54.7		$	37.1
Term loans	400.0			—
Less: unamortized debt issuance cost	(0.1		)	—
Short-term Debt	$	454.6		$	37.1

Revolving credit	$	—		$	439.0
Term loans	1,475.0			1,550.0
Other	0.2			0.2
Less: unamortized debt issuance cost	(2.9		)	(3.5		)
Long-term Debt	$	1,472.3		$	1,985.7

Total Debt	$	1,926.9		$	2,022.8

Earnings Per Share (Tables)

6 Months Ended

Apr. 30, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2019		2018		2019		2018
Net income (loss)	$	122.4	$	60.9	$	225.5	$	(61.6	)
Basic:
Weighted average common shares	49.4		49.1		49.3		49.0
Basic earnings (loss) per share	$	2.48	$	1.24	$	4.57	$	(1.26	)
Diluted:
Weighted average common shares	49.4		49.1		49.3		49.0
Effect of potential dilutive shares	0.6		0.5		0.6		—
Diluted weighted average common shares*	50.0		49.6		49.9		49.0
Diluted earnings (loss) per share attributable to Cooper stockholders	$	2.45	$	1.23	$	4.52	$	(1.26	)
*The number of diluted weighted average common shares used to calculate fiscal 2018 six months diluted loss per share excludes all potentially dilutive instrument because they would be antidilutive due to the net loss position.

Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation



Periods Ended April 30,	Three Months				Six Months
(In thousands, except exercise prices)	2019		2018		2019	2018
Number of stock option shares excluded	198		199		322	1,145
Range of exercise prices	$	254.77	$	229.66	$226.30-$254.77	$15.83-$229.66
Numbers of restricted stock units excluded	25		81		26	575

Share-Based Compensation Plans (Tables)

6 Months Ended

Apr. 30, 2019

Share-based Compensation [Abstract]

Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards

The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2019		2018		2019		2018
Selling, general and administrative expense	$	6.1	$	12.8	$	15.3	$	23.6
Cost of sales	1.4		0.3		2.9		1.6
Research and development expense	0.9		0.5		1.9		1.1
Total share-based compensation expense	$	8.4	$	13.6	$	20.1	$	26.3
Related income tax benefit	$	1.1	$	3.1	$	2.9	$	5.6

Stockholders' Equity (Tables)

6 Months Ended

Apr. 30, 2019

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Analysis of Changes in Accumulated Other Comprehensive (Loss) Income:



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2017	$	(353.7	)	$	(21.6	)	$	(375.3	)
Gross change in value during the year ended October 31, 2018	(58.5		)	11.0			(47.5		)
Tax effect for the period	—			(3.1		)	(3.1		)
ASU 2018-02 adoption⁽¹⁾	—			(4.8		)	(4.8		)
Balance at October 31, 2018	$	(412.2	)	$	(18.5	)	$	(430.7	)
Gross change in value during the six months ended April 30, 2019	14.1			—			14.1
Balance at April 30, 2019	$	(398.1	)	$	(18.5	)	$	(416.6	)


⁽¹⁾	Represents reclassification to retained earnings from adoption of ASU 2018-02. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 for more details.

Employee Benefits (Tables)

6 Months Ended

Apr. 30, 2019

Retirement Benefits, Description [Abstract]

Schedule of Components of Net Periodic Pension Costs

Our results of operations for the three and six months ended April 30, 2019 and 2018, reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2019			2018			2019			2018
Service cost	$	2.7		$	2.7		$	5.4		$	5.4
Interest cost	1.3			1.3			2.5			2.5
Expected return on plan assets	(2.3		)	(2.3		)	(4.6		)	(4.6		)
Recognized net actuarial loss	0.4			0.4			0.8			0.8
Net periodic pension cost	$	2.1		$	2.1		$	4.1		$	4.1

Business Segment Information (Tables)

6 Months Ended

Apr. 30, 2019

Segment Reporting [Abstract]

Schedule of Segment Information

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2019			2018			2019			2018
CooperVision net sales by category:
Toric lens	$	155.3		$	150.8		301.3			288.6
Multifocal lens	49.7			49.1			98.7			96.1
Single-use sphere lens	135.3			124.4			267.3			240.7
Non single-use sphere and other	143.9			143.2			287.0			286.9
Total CooperVision net sales	484.2			467.5			954.3			912.3
CooperSurgical net sales by category:
Office and surgical procedures	105.7			97.9			201.4			186.0
Fertility	64.4			65.9			126.7			123.0
CooperSurgical net sales	170.1			163.8			328.1			309.0
Total net sales	$	654.3		$	631.3		$	1,282.4		$	1,221.3
Operating income:
CooperVision	$	125.5		$	123.5		$	241.7		$	235.8
CooperSurgical	31.1			(29.8		)	38.3			(39.2		)
Corporate	(9.7		)	(19.0		)	(22.2		)	(31.8		)
Total operating income	146.9			74.7			257.8			164.8
Interest expense	18.5			18.7			36.6			37.1
Other expense (income), net	0.3			2.0			(0.7		)	(1.1		)
Income before income taxes	$	128.1		$	54.0		$	221.9		$	128.8

Schedule of Identifiable Assets by Segment



(In millions)	April 30, 2019		October 31, 2018
Total identifiable assets:
CooperVision	$	3,833.3	$	3,746.0
CooperSurgical	2,191.4		2,201.7
Corporate	178.7		165.1
Total	$	6,203.4	$	6,112.8

Schedule of Net Sales to External Customers by Country of Domicile

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2019		2018		2019		2018
Net sales to unaffiliated customers by country of domicile:
United States	$	305.9	$	293.2	$	584.9	$	554.6
Europe	209.5		210.4		419.2		413.8
Rest of world	138.9		127.7		278.3		252.9
Total	$	654.3	$	631.3	$	1,282.4	$	1,221.3

Schedule of Long-Lived Assets by Country of Domicile



(In millions)	April 30, 2019		October 31, 2018
Net property, plant and equipment by country of domicile:
United States	$	558.7	$	516.7
Europe	345.6		340.7
Rest of world	128.4		118.6
Total	$	1,032.7	$	976.0

General (Details) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Apr. 30, 2019

Nov. 01, 2018

Nov. 01, 2017

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative effect, decrease to retained earnings

$ 13.3

^[1]

$ (4.8)

Factoring fees associated with sale of factored receivables

$ 0.5

$ 0.9

Accounting Standards Update 2016-16 | Retained Earnings

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative effect, decrease to retained earnings

^[1]

$ 13.3

[1]	We adopted ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory in the first quarter of fiscal 2019. Refer to “Note 1. General" for further information.

Revenue Recognition (Details) $ in Millions	Apr. 30, 2019 USD ($)
Revenue from Contract with Customer [Abstract]
Refund liability for product returns	$ 10.6

Acquisitions (Details) - USD ($) $ in Millions		6 Months Ended	12 Months Ended
Acquisitions (Details) - USD ($) $ in Millions	Nov. 01, 2017	Apr. 30, 2019	Oct. 31, 2018	Oct. 31, 2017
Business Acquisition [Line Items]
Goodwill (Note 5)		$ 2,438.5	$ 2,392.1	$ 2,354.8
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		27.2	1,189.6
Net tangible assets		1.3	59.6
Total purchase consideration		64.3	1,319.8
Goodwill (Note 5)		35.8	70.6
Paragard
Business Acquisition [Line Items]
Property, plant and equipment	$ 2.0
Inventory	47.3
Other assets	9.4
Total assets acquired	1,121.8
Less: liabilities assumed	16.4
Net tangible assets	1,105.4
Total purchase consideration	1,100.0
Inventory step up	45.4
Technology \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		10.0	0.0
Customer relationships \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		7.5	23.5
Trademarks \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		9.7	100.0
Composite intangible asset \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		0.0	1,061.9
Composite intangible asset \| Paragard
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 1,061.9
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Other \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		$ 0.0	$ 4.2
Assembled Workforce \| Paragard
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 1.2
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 122.6	$ 112.5
Work-in-process	12.3	12.6
Finished goods	358.2	343.7
Inventories, net	$ 493.1	$ 468.8

Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018
Goodwill [Roll Forward]
Balance, beginning	$ 2,392.1	$ 2,354.8
Net additions during the six months ended April 30, 2019	35.8	71.2
Translation	10.6	(33.9)
Balance, ending	2,438.5	2,392.1
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,742.9	1,735.7
Net additions during the six months ended April 30, 2019	13.8	36.8
Translation	11.2	(29.6)
Balance, ending	1,767.9	1,742.9
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	649.2	619.1
Net additions during the six months ended April 30, 2019	22.0	34.4
Translation	(0.6)	(4.3)
Balance, ending	$ 670.6	$ 649.2

Intangible Assets (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,032.6		$ 2,032.6		$ 2,012.1
Accumulated Amortization	567.4		567.4		499.7
Intangible assets with definite lives, net	1,465.2		1,465.2		1,512.4
Intangible assets with indefinite lives, net	8.9		8.9		8.9
Total other intangible assets, net	1,474.1		$ 1,474.1		1,521.3
Finite-Lived Intangible Asset, Useful Life			14 years
Proceeds from sale of exclusive distribution right to distribute Filshie Clip System in the U.S.	21.0
Gain on sale of exclusive distribution right to distribute Filshie Clip System in the U.S.	19.0	$ 0.0	$ 19.0	$ 0.0
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	147.8		147.8		138.1
Accumulated Amortization	22.0		$ 22.0		16.9
Finite-Lived Intangible Asset, Useful Life			14 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,061.9		$ 1,061.9		1,061.9
Accumulated Amortization	106.1		$ 106.1		70.8
Finite-Lived Intangible Asset, Useful Life			15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	397.9		$ 397.9		387.2
Accumulated Amortization	206.1		$ 206.1		190.7
Finite-Lived Intangible Asset, Useful Life			11 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	357.7		$ 357.7		350.0
Accumulated Amortization	181.3		$ 181.3		168.6
Finite-Lived Intangible Asset, Useful Life			13 years
License and distribution rights and other(1)
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	67.3		$ 67.3		74.9
Accumulated Amortization	$ 51.9		$ 51.9		$ 52.7
Finite-Lived Intangible Asset, Useful Life			7 years

Intangible Assets (Narrative) (Details)	3 Months Ended
Intangible Assets (Narrative) (Details)	Apr. 30, 2019 USD ($) reporting_unit	Jul. 31, 2018 USD ($)	Jul. 31, 2017 USD ($)	Oct. 31, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Goodwill, Impairment Loss		$ 0	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2019	$ 71,800,000
2020	135,500,000
2021	134,200,000
2022	132,400,000
2023	130,100,000
Thereafter	861,200,000
Intangible assets with definite lives, net	$ 1,465,200,000			$ 1,512,400,000
CooperSurgical
Finite-Lived Intangible Assets [Line Items]
Number of reporting units \| reporting_unit	2

Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Short-term:
Overdraft and other credit facilities	$ 54.7	$ 37.1
Term loans	400.0	0.0
Less: unamortized debt issuance cost	(0.1)	0.0
Short-term Debt	454.6	37.1
Short-term Debt
Revolving credit	0.0	439.0
Term loans	1,475.0	1,550.0
Other	0.2	0.2
Less: unamortized debt issuance cost	(2.9)	(3.5)
Long-term debt	1,472.3	1,985.7
Total Debt	$ 1,926.9	$ 2,022.8

Debt (Narrative) (Details)				3 Months Ended	6 Months Ended
Debt (Narrative) (Details)	Nov. 01, 2018 USD ($)	Nov. 01, 2017 USD ($)	Mar. 01, 2016 USD ($)	Apr. 30, 2019 USD ($)	Apr. 30, 2019 USD ($)	Oct. 31, 2018 USD ($)
Line of Credit Facility [Line Items]
Short-term debt (Note 6)				$ 454,600,000	$ 454,600,000	$ 37,100,000
Term loans				$ 1,475,000,000	$ 1,475,000,000	$ 1,550,000,000
Required minimum Interest coverage ratio					3.00
Required maximum total leverage ratio					3.75
Interest coverage ratio				11.17	11.17
Total leverage ratio				1.99	1.99
Minimum
Line of Credit Facility [Line Items]
Commitment fee percentage			0.125%
Maximum
Line of Credit Facility [Line Items]
Commitment fee percentage			0.25%
2016 Credit Agreement
Line of Credit Facility [Line Items]
Line of credit facility, potential additional borrowing capacity			$ 750,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Aggregate commitment amount of credit facility			$ 1,000,000,000.0
2017 Term Loan \| Base Rate \| Minimum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.00%
2017 Term Loan \| Base Rate \| Maximum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.75%
2017 Term Loan \| London Interbank Offered Rate (LIBOR) \| Minimum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		1.00%
2017 Term Loan \| London Interbank Offered Rate (LIBOR) \| Maximum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		1.75%
2016 Credit Agreement
Line of Credit Facility [Line Items]
Line of credit facility, initiation date			Mar. 01, 2016
Term loans			$ 830,000,000
Line of credit facility interest rate margin on base rate loans percentage			1.00%
Line of credit facility interest rate margin on foreign currency loans percentage			1.75%
Amount available under the credit agreement				$ 999,500,000	$ 999,500,000
2016 Credit Agreement \| Federal Funds Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate			0.00%
2016 Credit Agreement \| Eurodollar
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Line of Credit
Line of Credit Facility [Line Items]
Debt instrument, maturity date			Mar. 01, 2021
Term Loan Agreement 2019 \| Senior Notes
Line of Credit Facility [Line Items]
Debt term	364 days
Debt instrument, face amount	$ 400,000,000.0
Short-term debt (Note 6)				$ 400,000,000	$ 400,000,000
Weighted average interest rate				3.10%	3.04%
Term Loan Agreement 2019 \| Senior Notes \| Base Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Term Loan Agreement 2019 \| Senior Notes \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.60%
Senior Unsecured Term Loan Agreement \| Senior Notes
Line of Credit Facility [Line Items]
Debt term		5 years
Debt instrument, face amount		$ 1,425,000,000
Interest rate				3.75%	3.75%
Term loans				$ 1,425,000,000	$ 1,425,000,000
Amount outstanding on credit agreement					$ 50,000,000

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Apr. 30, 2019	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2018
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit) to finalize tax effects of 2017 Act	$ (4.4)
Effective income tax rate expense (benefit)	4.50%	(12.90%)		(1.70%)	147.80%
Change of provisional tax expenses related to 2017 Act			$ 202.0
Discrete tax benefits	$ 23.1
Unrecognized tax benefits	49.1			$ 49.1		$ 68.9
Unrecognized tax benefits that could be settled	$ 3.1			$ 3.1

Earnings Per Share (Schedule of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2019	Apr. 30, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ 122.4	$ 103.2	$ 60.9	$ (122.5)	$ 225.5	$ (61.6)
Basic:
Weighted average common shares	49.4		49.1		49.3	49.0
Basic earnings (loss) per share	$ 2.48		$ 1.24		$ 4.57	$ (1.26)
Diluted:
Effect of potential dilutive shares	0.6		0.5		0.6	0.0
Diluted weighted average common shares	50.0		49.6		49.9	49.0
Diluted earnings (loss) per share attributable to Cooper stockholders	$ 2.45		$ 1.23		$ 4.52	$ (1.26)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Share (Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	198	199	322	1,145
Range of exercise prices, lower limit	$ 254.77	$ 229.66	$ 226.3	$ 15.83
Range of exercise prices, upper limit	$ 254.77	$ 229.66	$ 254.77	$ 229.66
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	25	81	26	575

Share-Based Compensation Plans - Schedule of Compensation Expense And Related Income Tax Benefit For Share-Based Awards (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 8.4	$ 13.6	$ 20.1	$ 26.3
Related income tax benefit	1.1	3.1	2.9	5.6
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	6.1	12.8	15.3	23.6
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1.4	0.3	2.9	1.6
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0.9	$ 0.5	$ 1.9	$ 1.1

Share-Based Compensation Plans - Narrative (Details) - shares	Mar. 18, 2019	Apr. 30, 2019	Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock (in shares)		3,600,000	3,600,000
Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP purchase price of common stock, percent of market price	85.00%
ESPP shares authorized (in shares)	1,000,000

Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions

6 Months Ended

12 Months Ended

Apr. 30, 2019

Oct. 31, 2018

Nov. 01, 2018

^[1]

Nov. 01, 2017

Class of Stock [Line Items]

ASU 2016-16 adoption

$ (13.3)

$ 4.8

Foreign Currency Translation Adjustment [Roll Forward]

Foreign Currency Translation Adjustment, Beginning Balance

$ (412.2)

$ (353.7)

Foreign Currency Translation Adjustment, Gross change in value for the period

14.1

(58.5)

Foreign Currency Translation Adjustment, tax effect

0.0

Foreign Currency Translation Adjustment, Ending Balance

(398.1)

(412.2)

Minimum Pension Liability [Roll Forward]

Minimum Pension Liability, Beginning Balance

(18.5)

(21.6)

Minimum Pension Liability, Gross change in value for the period

0.0

11.0

Minimum Pension Liability, tax effect

(3.1)

Minimum Pension Liability, Ending Balance

(18.5)

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Total, Beginning balance

(430.7)

(375.3)

Gross change in value for the period

14.1

(47.5)

Tax effect for the period

(3.1)

Total, Ending balance

$ (416.6)

$ (430.7)

Foreign Currency Translation Adjustment

Class of Stock [Line Items]

ASU 2016-16 adoption

0.0

Minimum Pension Liability

Class of Stock [Line Items]

ASU 2016-16 adoption

$ 4.8

[1]	We adopted ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory in the first quarter of fiscal 2019. Refer to “Note 1. General" for further information.

Stockholders' Equity (Share Repurchases) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Mar. 01, 2017	Feb. 28, 2017
Equity [Abstract]
Share Repurchase Program, maximum amount authorized				$ 1,000,000,000.0	$ 500,000,000.0
Average purchase price (in usd per share)		$ 248.70
Number of common stock repurchased, shares	0	24,500	0
Treasury Stock, Value, Acquired, Cost Method		$ 6,100,000
Share Repurchase Program, remaining authorized amount	$ 557,400,000

Stockholders' Equity (Dividends) (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Feb. 08, 2019	Apr. 30, 2019	Apr. 30, 2018
Equity [Abstract]
Dividends on common stock	$ 1.5	$ 1.5	$ 1.5
Cash dividend, per share	$ 0.03
Dividends payable, date of record	Jan. 22, 2019

Employee Benefits (Schedule of Components of Net Periodic Pension Costs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Retirement Benefits, Description [Abstract]
Service cost	$ 2.7	$ 2.7	$ 5.4	$ 5.4
Interest cost	1.3	1.3	2.5	2.5
Expected return on plan assets	(2.3)	(2.3)	(4.6)	(4.6)
Recognized net actuarial loss	0.4	0.4	0.8	0.8
Net periodic pension cost	$ 2.1	$ 2.1	$ 4.1	$ 4.1

Employee Benefits (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Retirement Benefits, Description [Abstract]
Defined benefit plan, contributions by employer	$ 2,500	$ 2,500
Defined benefit plan, estimated future employer contributions in current fiscal year	$ 7,500
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details) $ in Millions	26 Months Ended
Contingencies (Details) $ in Millions	Apr. 30, 2017 action	Jul. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of putative class action complaints filed (over) \| action	50
Litigation Settlement, Amount \| $		$ 3.0

Business Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Segment Reporting Information [Line Items]
Net sales (Note 2)	$ 654.3	$ 631.3	$ 1,282.4	$ 1,221.3
Operating income (loss)	146.9	74.7	257.8	164.8
Interest expense	18.5	18.7	36.6	37.1
Other expense (income), net	0.3	2.0	(0.7)	(1.1)
Income before income taxes	128.1	54.0	221.9	128.8
CooperVision
Segment Reporting Information [Line Items]
Net sales (Note 2)	484.2	467.5	954.3	912.3
Operating income (loss)	125.5	123.5	241.7	235.8
CooperSurgical
Segment Reporting Information [Line Items]
Net sales (Note 2)	170.1	163.8	328.1	309.0
Operating income (loss)	31.1	(29.8)	38.3	(39.2)
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(9.7)	(19.0)	(22.2)	(31.8)
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales (Note 2)	155.3	150.8	301.3	288.6
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales (Note 2)	49.7	49.1	98.7	96.1
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales (Note 2)	135.3	124.4	267.3	240.7
Non single-use sphere and other \| CooperVision
Segment Reporting Information [Line Items]
Net sales (Note 2)	143.9	143.2	287.0	286.9
Office and surgical procedures \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales (Note 2)	105.7	97.9	201.4	186.0
Fertility \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales (Note 2)	$ 64.4	$ 65.9	$ 126.7	$ 123.0

Business Segment Information (Schedule of Identifiable Assets By Segment Information) (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 6,203.4	$ 6,112.8
CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	3,833.3	3,746.0
CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	2,191.4	2,201.7
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 178.7	$ 165.1

Business Segment Information (Schedule of Net Sales To External Customers By Country Of Domicile) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 654.3	$ 631.3	$ 1,282.4	$ 1,221.3
United States
Segment Reporting Information [Line Items]
Total net sales to external customers	305.9	293.2	584.9	554.6
Europe
Segment Reporting Information [Line Items]
Total net sales to external customers	209.5	210.4	419.2	413.8
Rest of world
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 138.9	$ 127.7	$ 278.3	$ 252.9

Business Segment Information (Schedule of Long-Lived Assets By Country Of Domicile) (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Segment Reporting Information [Line Items]
Total long-lived assets	$ 1,032.7	$ 976.0
United States
Segment Reporting Information [Line Items]
Total long-lived assets	558.7	516.7
Europe
Segment Reporting Information [Line Items]
Total long-lived assets	345.6	340.7
Rest of world
Segment Reporting Information [Line Items]
Total long-lived assets	$ 128.4	$ 118.6

Label	Element	Value
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 400,000
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 300,000